Can apixaban (Eliquis) be used in a patient with active infective endocarditis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban Should NOT Be Used in Active Infective Endocarditis

Do not use apixaban (or any anticoagulation) in patients with active infective endocarditis unless there is a separate, compelling indication for anticoagulation (such as mechanical prosthetic heart valve or atrial fibrillation), and even then, the decision requires extreme caution and multidisciplinary consultation.

Key Reasoning

FDA Labeling Explicitly Excludes This Population

The FDA label for apixaban (Eliquis) states that "the safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients" 1. While this specifically addresses prosthetic valves, it reflects the broader concern about using DOACs in valvular pathology with high thrombotic and bleeding risk—which endocarditis represents.

Anticoagulation Does NOT Prevent Embolic Events in IE

The fundamental principle is that infective endocarditis alone is NOT an indication for anticoagulation 2. Research demonstrates that anticoagulation fails to reduce ischemic stroke risk in IE patients 3, 2. The embolic events in IE result from infected vegetations breaking off, not from traditional thrombus formation—anticoagulation cannot prevent this mechanical process.

Increased Bleeding Risk Outweighs Any Theoretical Benefit

Patients with IE face catastrophic bleeding complications when anticoagulated:

  • Intracerebral hemorrhage occurs in ~5% of IE patients and is the leading cause of death in anticoagulated patients 4
  • In prosthetic valve endocarditis, 36% of anticoagulated patients developed symptomatic cerebral hemorrhage with 80% mortality 5
  • Anticoagulated patients have significantly higher rates of cerebrovascular accidents (19/94 vs 19/238, p<0.01) 6

Clinical Algorithm for Decision-Making

Step 1: Confirm IE Diagnosis

If active IE is confirmed, default position is NO anticoagulation unless compelling alternative indication exists.

Step 2: Assess for Pre-existing Anticoagulation Indications

If patient has mechanical prosthetic valve:

  • Continue anticoagulation with warfarin (NOT apixaban—DOACs contraindicated) 1
  • Monitor closely for bleeding complications
  • Consider temporary discontinuation if intracranial hemorrhage occurs

If patient has atrial fibrillation:

  • Discontinue apixaban during active IE phase 2
  • Reassess need after completing antibiotic course and documenting vegetation resolution
  • If stroke occurs during IE, maintain heparin anticoagulation unless hemorrhagic transformation 6

If patient on dual antiplatelet therapy (post-PCI):

  • No clear data available 4
  • Consider reducing to single antiplatelet agent
  • Consult cardiology urgently

Step 3: Monitor for Complications

If ischemic stroke occurs during IE:

  • Do NOT start anticoagulation reflexively
  • Obtain urgent brain imaging to exclude hemorrhage
  • If large or hemorrhagic infarct: absolutely contraindicated
  • If small non-hemorrhagic infarct: consider heparin (NOT apixaban) only after infectious disease consultation 6

If intracranial hemorrhage occurs:

  • Immediately discontinue all anticoagulation 1
  • Apixaban effect persists 24 hours after last dose 1
  • Consider reversal agent (andexanet alfa) if available
  • Do not restart anticoagulation during active IE

Special Considerations

Why Not Apixaban Specifically?

  1. No reversal experience in IE bleeding emergencies 1
  2. Cannot be monitored with standard coagulation tests 1
  3. Contraindicated in active pathological bleeding—and IE carries high bleeding risk 1
  4. Not studied in prosthetic valves or IE populations 1

Single Exception: Low-Dose Aspirin

Recent evidence suggests low-dose aspirin (75-100mg) after hospitalization may reduce mortality without increasing hemorrhagic stroke 4. This is NOT the same as therapeutic anticoagulation with apixaban.

Common Pitfalls to Avoid

  1. Do not reflexively continue home anticoagulation when IE is diagnosed—reassess indication
  2. Do not start apixaban for "stroke prevention" in IE—it doesn't work and increases bleeding risk
  3. Do not use apixaban as bridge therapy in IE patients with mechanical valves—use heparin or warfarin only
  4. Do not restart anticoagulation immediately after embolic stroke in IE—obtain imaging first and consult neurology

Bottom Line

Apixaban has no role in active infective endocarditis. If the patient was on apixaban for atrial fibrillation when IE developed, stop it during the active infection phase. If they have a mechanical valve requiring anticoagulation, use warfarin instead. The only scenario where continuing anticoagulation might be considered is a patient with pre-existing mechanical prosthetic valve (using warfarin, not apixaban) who develops IE, and even then, the risk-benefit must be continuously reassessed with infectious disease and cardiology specialists 2.

Related Questions

Should a patient with infective endocarditis who has an acute stroke receive antiplatelet therapy or systemic anticoagulation, and if so, what timing and dosing are recommended?
Is anticoagulation indicated in a patient with infective endocarditis without another clear indication?
When should apixaban (Eliquis) be initiated after stopping a heparin infusion?
In a patient with acute kidney injury, septic shock, and a portal‑splenic vein thrombus extending from the splenic vein to the portal vein who is currently on apixaban (Eliquis), how should anticoagulation be managed?
In a 71-year-old male with end‑stage renal disease on dialysis who is taking duloxetine 60 mg daily for major depressive disorder and apixaban for prior cerebrovascular accident, can the duloxetine dose be increased?
For a 50-year-old woman receiving her scheduled Depo‑Provera injection who has been off sertraline 50 mg and buspirone 15 mg for about five weeks, can both medications be restarted simultaneously, and what initial dosing should be used?
What is the appropriate workup for a 72-year-old man with syncope episodes and hyperlipidemia?
How should carboplatin be dosed and administered in adult cancer patients, including renal function considerations, target AUC, infusion schedule, hydration, anti‑emetic prophylaxis, and monitoring?
A patient currently taking Adderall XR (mixed amphetamine salts) 30 mg daily wishes to switch to Focalin (dexmethylphenidate). What initial dose of Focalin is most appropriate—5 mg or 15 mg?
How can I identify an abnormal neurovascular examination of the foot?
What is the appropriate treatment for a 17-year-old with a thickened skin blister (callus) under the hallux?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.